US 12,390,458 B2
Therapeutic combination of quinoline derivative and antibody
Xin Tian, Nanjing (CN); Chen Shen, Nanjing (CN); Peng Lyu, Nanjing (CN); Xiangjian Wang, Nanjing (CN); Xiquan Zhang, Nanjing (CN); Zheng Liu, Nanjing (CN); Yu Xia, Zhongshan (CN); Xiaoping Jin, Zhongshan (CN); Baiyong Li, Zhongshan (CN); Zhongmin Maxwell Wang, Zhongshan (CN); Baohui Han, Shanghai (CN); Tianqing Chu, Shanghai (CN); Hua Zhong, Shanghai (CN); and Rong Li, Shanghai (CN)
Assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang (CN)
Appl. No. 17/260,398
Filed by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang (CN)
PCT Filed Jul. 18, 2019, PCT No. PCT/CN2019/096540
§ 371(c)(1), (2) Date Jan. 14, 2021,
PCT Pub. No. WO2020/015703, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 201810790198.6 (CN), filed on Jul. 18, 2018; application No. 201811346173.6 (CN), filed on Nov. 13, 2018; and application No. 201910149525.4 (CN), filed on Feb. 28, 2019.
Prior Publication US 2022/0160700 A1, May 26, 2022
Int. Cl. A61K 31/4709 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A therapeutic combination, comprising:
a) an inhibitor for the interaction between PD-1 and its ligand PD-L1, wherein the inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof, and wherein the anti-PD-1 antibody is sintilimab and
b) a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry